These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 24019539

  • 1. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.
    J Clin Oncol; 2013 Oct 10; 31(29):3664-72. PubMed ID: 24019539
    [Abstract] [Full Text] [Related]

  • 2. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.
    JAMA Oncol; 2017 Apr 01; 3(4):472-480. PubMed ID: 28006055
    [Abstract] [Full Text] [Related]

  • 3. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA.
    JAMA Oncol; 2018 Mar 01; 4(3):379-383. PubMed ID: 28983557
    [Abstract] [Full Text] [Related]

  • 4. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
    Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology.
    Clin Cancer Res; 2014 Jun 01; 20(11):3033-43. PubMed ID: 24687927
    [Abstract] [Full Text] [Related]

  • 5. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.
    J Clin Oncol; 2015 Dec 10; 33(35):4176-87. PubMed ID: 26527776
    [Abstract] [Full Text] [Related]

  • 6. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).
    Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology.
    Clin Cancer Res; 2015 Dec 01; 21(23):5294-304. PubMed ID: 26187617
    [Abstract] [Full Text] [Related]

  • 7. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.
    Gastroenterology; 2015 Jan 01; 148(1):88-99. PubMed ID: 25305506
    [Abstract] [Full Text] [Related]

  • 8. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA.
    J Natl Cancer Inst; 2017 May 01; 109(5):. PubMed ID: 28040692
    [Abstract] [Full Text] [Related]

  • 9. Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147.
    Phipps AI, Shi Q, Newcomb PA, Nelson GD, Sargent DJ, Alberts SR, Limburg PJ.
    J Clin Oncol; 2013 Jun 01; 31(16):2016-23. PubMed ID: 23547084
    [Abstract] [Full Text] [Related]

  • 10. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.
    J Natl Cancer Inst; 2011 Jun 08; 103(11):863-75. PubMed ID: 21597022
    [Abstract] [Full Text] [Related]

  • 11. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW, Kim KJ, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.
    Ann Surg Oncol; 2015 Jan 08; 22(1):187-94. PubMed ID: 24889488
    [Abstract] [Full Text] [Related]

  • 12. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C, PETACC-8 Study Investigators.
    Lancet Oncol; 2014 Jul 08; 15(8):862-73. PubMed ID: 24928083
    [Abstract] [Full Text] [Related]

  • 13. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T.
    Ann Oncol; 2019 Sep 01; 30(9):1466-1471. PubMed ID: 31268130
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
    Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T, Raptou G, Vrettou E, Sgouros J, Samantas E, Basdanis G, Papakostas P, Bafaloukos D, Kotoula V, Kalofonos HP, Scopa CD, Pentheroudakis G, Fountzilas G.
    BMC Cancer; 2015 May 10; 15():384. PubMed ID: 25956750
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
    Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanan A, Laurent-Puig P, PETACC8 Investigators.
    Ann Oncol; 2017 Apr 01; 28(4):824-830. PubMed ID: 28031175
    [Abstract] [Full Text] [Related]

  • 16. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
    Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P.
    J Clin Oncol; 2011 Apr 01; 29(10):1261-70. PubMed ID: 21383284
    [Abstract] [Full Text] [Related]

  • 17. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.
    Clin Cancer Res; 2011 Dec 01; 17(23):7470-8. PubMed ID: 21998335
    [Abstract] [Full Text] [Related]

  • 18. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
    Qin Q, Zhou AP, Yang L, Xu C, Sun YK, Zhang W, Wang JW, Zhong DS.
    J Physiol Pharmacol; 2020 Aug 01; 71(4):. PubMed ID: 33316771
    [Abstract] [Full Text] [Related]

  • 19. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.
    Sinicrope FA, Chakrabarti S, Laurent-Puig P, Huebner L, Smyrk TC, Tabernero J, Mini E, Goldberg RM, Zaanan A, Folprecht G, Van Laethem JL, Le Malicot K, Shi Q, Alberts SR, Taieb J.
    Eur J Cancer; 2021 Feb 01; 144():101-112. PubMed ID: 33341444
    [Abstract] [Full Text] [Related]

  • 20. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.
    Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ.
    J Clin Oncol; 2012 Feb 01; 30(4):406-12. PubMed ID: 22203756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.